Digostics

Einzelheiten

Land

Großbritannien

Typologie

Eigenkapital

Endtermin

05/08/2025 (325 Tage)

Investoren

160

“Digostics is transforming diabetes care with GTT@home — the world’s first at-home oral glucose tolerance test (OGTT). Our CE-marked digital platform delivers home-based diabetes screening, supporting earlier detection and relieving healthcare system pressures. Adopted by NHS Trusts and approved in multiple markets, Digostics is redefining diabetes detection.”